According to the National Institutes of Health (NIH), the hepatitis C virus is spreading at a faster rate among Americans than HIV/AIDS and currently affects approximately 4 million people in the U.S.
Whether you are considering or beginning PEG-INTRON® treatment, use this page to hear how other people have successfully managed treatment and beaten hepatitis C. Hearing real life stories like the ones told by Jackie, a 41-year-old nurse, or Jim, a 58-year-old jazz musician, can help you to learn about living with hepatitis C and what's involved with treatment.
In a clinical trial with PEG-INTRON®/REBETOL® (Ribavirin, USP) Capsules combination therapy, 52% of patients achieved SVR.
The people presented here are real patients who have successfully completed PEG-INTRON®/REBETOL® (Ribavirin, USP) Capsules combination therapy. They have agreed to allow Schering Corporation to use their photographs and stories on this Web site. No compensation has been given to any of these individuals.
